Hostname: page-component-89b8bd64d-4ws75 Total loading time: 0 Render date: 2026-05-06T00:11:55.688Z Has data issue: false hasContentIssue false

Improved serodiagnosis of alveolar echinococcosis of humans using an in vitro-produced Echinococcus multilocularis antigen

Published online by Cambridge University Press:  19 February 2007

N. MÜLLER*
Affiliation:
Institute of Parasitology, University of Berne, Berne, Switzerland
E. FREI
Affiliation:
Institute of Parasitology, University of Berne, Berne, Switzerland
S. NUÑEZ
Affiliation:
Institute of Parasitology, University of Berne, Berne, Switzerland
B. GOTTSTEIN*
Affiliation:
Institute of Parasitology, University of Berne, Berne, Switzerland
*
*Corresponding authors: Institute of Parasitology, Länggass-Strasse 122, CH-3012 Berne, Switzerland. Tel: +41 31 6312474 or +41 31 6312418. Fax: +41 31 6312622. E-mail: nmueller@ipa.unibe.ch or bruno.gottstein@ipa.unibe.ch
*Corresponding authors: Institute of Parasitology, Länggass-Strasse 122, CH-3012 Berne, Switzerland. Tel: +41 31 6312474 or +41 31 6312418. Fax: +41 31 6312622. E-mail: nmueller@ipa.unibe.ch or bruno.gottstein@ipa.unibe.ch

Summary

Serology is an important tool for the diagnosis of alveolar echinococcosis (AE) in humans. In order to improve serodiagnostic performance, we have developed an in vitro-produced Echinococcus mulilocularis metacestode vesicle fluid (EmVF) antigen for application in an immunoblot assay. Immunoblot analysis of EmVF revealed an abundant immunoreactive band triplet of 20–22 kDa, achieving a sensitivity of 100% based on the testing of sera from 62 pre-operative and pre-treatment cases of active and inactive AE. Thus, the EmVF-immunoblotting allowed the specific detection of cases seronegative by the Em2- and/or EmII/3–10-ELISA, usually attributable to abortive, inactive cases of AE. The specificity of the EmVF-immunoblotting did not allow discrimination between AE and cystic echinococcosis (CE) but was 100% with respect to non-Echinococcus parasitic infections or cancer malignancies. Based on the findings of this study, it is recommended that the current ELISA test combination (Em2- and II/3–10-ELISA) be complemented with EmVF-immunoblotting, allowing an improved diagnosis of both clinical and subclinical forms of AE, including those associated with E. multilocularis-specific antibody reactivities not detectable by ELISA.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable